Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Suppressor APC domain containing 2 encodes a protein of approximately 42.3 kDa, initially recognized as a cell cycle-associated molecule critical for mitotic progression. SAPCD2 is not expressed in most healthy postnatal tissues, but its expression is strongly upregulated during embryogenesis and in various tumors. Structurally, SAPCD2 features a coiled-coil domain and proline-rich regions facilitating protein-protein interactions. Its cellular role encompasses regulation of spindle orientation, symmetric cell division, and modulation of the Wnt/β-catenin pathway—where SAPCD2 competes with protein phosphatase 2A (PP2A) for Axin1 binding, thereby reinforcing β-catenin phosphorylation and suppressing Wnt target gene activity[1]. SAPCD2 is being studied as both a diagnostic and therapeutic cancer target, and its interactions with key cell division and signaling proteins are partly understood but remain the subject of ongoing research. Recent evidence suggests it may play additional roles in inflammation and developmental biology[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Suppressor APC domain containing 2 (SAPCD2).